An engineered glutamic acid tRNA for efficient suppression of pathogenic nonsense mutations

Area of Science:

• Genetics
• Molecular Biology
• Biochemistry

Background:

• Nonsense mutations leading to premature termination codons (PTCs) cause genetic diseases.
• Current treatments for these diseases are limited.
• Engineered suppressor transfer RNAs (sup-tRNAs) offer a potential therapeutic strategy by enabling stop codon readthrough.

Purpose of the Study:

• To develop an effective sup-tRNA for suppressing PTCs at glutamic acid codons, a common mutation site.
• To demonstrate the ability of the rationally designed sup-tRNA (tRNAGluV13) to restore full-length protein synthesis.

Main Methods:

• Rational design of a novel sup-tRNA (tRNAGluV13) targeting glutamic acid codons.
• Testing tRNAGluV13 efficiency in restoring protein synthesis from reporter genes with PTCs.
• Evaluating tRNAGluV13 in preclinical models of hereditary breast and ovarian cancer syndrome and cystic fibrosis.

Main Results:

• tRNAGluV13 demonstrated high efficiency in suppressing PTCs at glutamic acid codons.
• The sup-tRNA successfully restored full-length protein synthesis in reporter gene assays.
• tRNAGluV13 showed functional rescue of pathogenic PTCs in models of genetic diseases.

Conclusions:

• The developed tRNAGluV13 significantly improves PTC suppression at glutamic acid codons.
• This advancement holds promise for expanding sup-tRNA-based therapeutics for a range of genetic disorders.
• tRNAGluV13 represents a promising candidate for treating diseases caused by common nonsense mutations.